Research Seminar Speaker Series: Brian O’Mara – “Downstream Process Development of Monoclonal Antibodies”

Please join us for our Research Seminar Speaker Series with Brian O’Mara, Associate Director, Downstream Process Development, Ambrx, Inc.

Monoclonal antibodies (mAb) have become a predominant class of therapeutic modalities used in the treatment of several disease indications, including cancers, autoimmune, metabolic, allograft rejection, and infectious diseases. The 2020 global mAb market was USD 157 billion with an anticipated growth to USD 450 billion in 2028. With more than 570 mAbs in sponsored clinical trials, Phase 1/2 clinical trials are critical milestones that determine safety and efficacy in the drug candidate. The safety and efficacy are pivotal responses in the drug’s development and are impacted by not only the drug’s mechanism of action and in vivo response, but also the mAb’s purity and level of impurities in the drug substance. Discussed here are key considerations and strategies for the efficient downstream development and manufacturing of mAb therapeutics to enable success in early-stage clinical trials.

Date: Friday, December 10, 2021

Time: 12:00 – 1:00 p.m.

Location: Via Zoom – Zoom Link will be included in the Outlook Invite